---
title: "Arcus Biosciences partners with AVEO Oncology to test casdatifan-tivozanib combo in kidney cancer study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293519299.md"
description: "Arcus Biosciences has entered a clinical supply agreement with AVEO Oncology to evaluate the combination of casdatifan and tivozanib in advanced clear cell renal cell carcinoma. The randomized ARC-20 cohort study will compare casdatifan plus tivozanib against tivozanib alone. Arcus will sponsor and conduct the trial, while each company retains rights to its respective drug."
datetime: "2026-07-22T20:40:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293519299.md)
  - [en](https://longbridge.com/en/news/293519299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293519299.md)
generator: "portal-rs"
---

# Arcus Biosciences partners with AVEO Oncology to test casdatifan-tivozanib combo in kidney cancer study

-   Arcus Biosciences signed a clinical supply agreement with AVEO Oncology to test casdatifan with AVEO’s kidney cancer drug tivozanib. \* The combo will be evaluated in a new randomized ARC-20 cohort in advanced clear cell renal cell carcinoma previously treated with a HIF-2α inhibitor. \* Study design compares casdatifan with tivozanib 1.34 mg versus tivozanib 1.34 mg alone; AVEO supplies tivozanib. \* Arcus will sponsor and run the trial; each company retains development and commercial rights to its own drug. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720389288) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RCUS.US](https://longbridge.com/en/quote/RCUS.US.md)

## Related News & Research

- [Does Arcus Biosciences’ (RCUS) AVEO Tie-Up Hint At A New Combo-First RCC Strategy?](https://longbridge.com/en/news/293782523.md)
- [Arcus Biosciences Chief Accounting Officer Alexander Azoy sells 2,827 shares for $84,810](https://longbridge.com/en/news/296832269.md)
- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [BUZZ-TScan Therapeutics falls after pausing cancer trial](https://longbridge.com/en/news/297781139.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**